Inventor
MAPELLI CLAUDIO
US29 patents
⚠️ This page may combine multiple inventors who share the name “MAPELLI CLAUDIO”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
25 patentsUS9308236B2Apr 12, 2016
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
BRISTOL MYERS SQUIBB CO51 citations96
US7417028B2Aug 26, 2008
Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
BRISTOL MYERS SQUIBB CO20 citations91
US7238671B2Jul 3, 2007
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
BRISTOL MYERS SQUIBB CO24 citations89
US7238670B2Jul 3, 2007
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
BRISTOL MYERS SQUIBB CO32 citations89
US10633419B2Apr 28, 2020
Immunomodulators
BRISTOL MYERS SQUIBB CO7 citations84
US9861680B2Jan 9, 2018
Immunomodulators
BRISTOL MYERS SQUIBB CO10 citations84
US9856292B2Jan 2, 2018
Immunomodulators
BRISTOL MYERS SQUIBB CO12 citations84
US10538555B2Jan 21, 2020
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
BRISTOL MYERS SQUIBB CO8 citations83
US10266578B2Apr 23, 2019
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
BRISTOL MYERS SQUIBB CO9 citations82
US9850283B2Dec 26, 2017
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
BRISTOL MYERS SQUIBB CO12 citations82
US11358988B2Jun 14, 2022
Immunomodulators
BRISTOL MYERS SQUIBB CO2 citations73
US10450347B2Oct 22, 2019
Immunomodulators
BRISTOL MYERS SQUIBB CO6 citations72
US5516642AMay 14, 1996
Polypeptides derived from major histocompatibility complex Class I antigen
BRISTOL MYERS SQUIBB CO16 citations71
US9605024B2Mar 28, 2017
PAR4 agonist peptides
BRISTOL MYERS SQUIBB CO4 citations69
US7314726B2Jan 1, 2008
Beta secretase exosite binding peptides and methods for identifying beta secretase modulators
BRISTOL MYERS SQUIBB CO6 citations67
US11952434B2Apr 9, 2024
Immunomodulators
BRISTOL MYERS SQUIBB CO0 citations62
US12097242B2Sep 24, 2024
Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
BRISTOL MYERS SQUIBB CO0 citations61
US12097241B2Sep 24, 2024
Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
BRISTOL MYERS SQUIBB CO0 citations61
US11364281B2Jun 21, 2022
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
BRISTOL MYERS SQUIBB CO0 citations61
US11185570B2Nov 30, 2021
Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
BRISTOL MYERS SQUIBB CO0 citations61
US7960349B2Jun 14, 2011
N-terminally modified GLP-1 receptor modulators
BRISTOL MYERS SQUIBB CO2 citations61
US9303065B2Apr 5, 2016
PAR4 agonist peptides
BRISTOL MYERS SQUIBB CO2 citations60
US8927688B2Jan 6, 2015
PAR4 agonist peptides
BRISTOL MYERS SQUIBB CO2 citations60
US7534763B2May 19, 2009
Sustained release GLP-1 receptor modulators
BRISTOL MYERS SQUIBB CO5 citations59
US9482665B2Nov 1, 2016
Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
BRISTOL MYERS SQUIBB CO0 citations42